Stocks
Funds
Screener
Sectors
Watchlists
PSNL

PSNL - Personalis Inc Stock Price, Fair Value and News

$8.59+0.38 (+4.63%)
Market Closed

13/100

PSNL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

13/100

PSNL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

PSNL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PSNL Price Action

Last 7 days

-0.4%

Last 30 days

-13.1%

Last 90 days

4.3%

Trailing 12 Months

55.9%

PSNL RSI Chart

PSNL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PSNL Valuation

Market Cap

762.8M

Price/Earnings (Trailing)

-10.32

Price/Sales (Trailing)

11.04

EV/EBITDA

-11.21

Price/Free Cashflow

-11.53

PSNL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

69.1M

Rev. Growth (Yr)

-43.62%

Rev. Growth (Qtr)

-15.74%

PSNL Earnings

Earnings (TTM)

-73.9M

Earnings Growth (Yr)

44.61%

Earnings Growth (Qtr)

-7.96%

PSNL Profitability

Operating Margin

26.67%

EBT Margin

-106.89%

Return on Equity

-43.1%

Return on Assets

-30.42%

Free Cashflow Yield

-8.67%

PSNL Investor Care

Shares Dilution (1Y)

25.70%

Diluted EPS (TTM)

-0.85

PSNL Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202585.7M80.3M69.1M0
202474.1M80.0M87.5M84.6M
202368.7M67.1M70.5M73.5M
202279.8M76.4M69.0M65.0M
202180.4M82.5M85.0M85.5M
202070.3M74.0M76.6M78.6M
201947.7M54.7M60.2M65.2M
201816.5M23.6M30.7M37.8M
20170009.4M
PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.
 CEO
 WEBSITEpersonalis.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES395

Personalis Inc Frequently Asked Questions


PSNL is the stock ticker symbol of Personalis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Feb 17 2026, market cap of Personalis Inc is 762.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Feb 17 2026, PSNL's PE ratio (Price to Earnings) is -10.32 and Price to Sales (PS) ratio is 11.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSNL PE ratio will change depending on the future growth rate expectations of investors.